Diabetology Xagena

Xagena Mappa
Medical Meeting

Search results for "GLP-1 agonist"

Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta ) twice-daily. The GetGoal-X Phase III stu ...

The American College of Physicians ( ACP ) has developed a guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medicat ...

Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy for type 2 diabetes mellitus that could provide robust glucose-loweri ...